According to the Veeva 2017 Unified Clinical Operations Survey, nearly all respondents (99%) agree there is a need to unify applications across clinical operations. Faster study execution and improved study quality were cited as the top drivers for such a model.
“When clinical applications are unified, they enable life sciences organizations to establish repeatable, collaborative processes, and increase oversight and accuracy by consistently leveraging insights across their clinical portfolios,” Jen Goldsmith, SVP of Veeva Vault told Outsourcing-Pharma.com.
According to Goldsmith, sponsors face challenges managing clinical trials due to the siloed nature of their processes and applications.
“The greater the number of different clinical applications an organization uses, the greater the negative impacts, particularly with complex processes such as study start-up,” she explained.
According to the report, sponsors face several deficiencies with their CTMS applications, including an inability to fully support functions like resource management (77%), study and site feasibility (76%), financial management (75%), and issue/task management (73%).
“The amount of data collected and the extent to which it is leveraged has a direct impact on improvements to clinical operations efficiency,” said Goldsmith. “Organizations using the most amount of data report the greatest number of improvements in audit readiness, collaboration, and monitoring activities.”
While Goldsmith commented that delayed information access is currently accepted as part of the process, moving forward, these manual processes will be streamlined.
“Different functional teams will be able to easily access the same piece of information in multiple ways,” she said.
“Streamlining the process of how data is used not only within clinical, but also other areas of the organization will empower life sciences to bring innovative new therapies and drugs to market much faster.”